P. Bachurski, “Optimal First-Line Use of Pembrolizumab in Metastatic Driver-Negative NSCLC: Monotherapy Versus Chemo-Immunotherapy (Evidence 2022–2025)”, Qual Sport, vol. 51, p. 68252, Jan. 2026.